Introduction Hypertrophic cardiomyopathy (HCM) is a primary myocardial disease commonly caused by pathogenic genetic variants encoding sarcomere proteins. Mavacamten. a first-in-class allosteric inhibitor of cardiac-specific myosin. has demonstrated efficacy and safety in international clinical trials of patients with symptomatic obstructive HCM (oHCM) but clinical evidence for mavaca... https://www.chiggate.com/biomat-sessions-sale/